ArticleTranslational cancer research2020
Incidence features of second primary malignancy among gastric cancer survivors, 1992-2012.
Article in Translational cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 6 citations in OpenAlex.
- Risk assessment of secondary primary malignancies: results from two large prospective European cohorts.NPJ precision oncology · 2026Article
- The risk and distribution of second primary cancers according to subsite of primary stomach cancer: a retrospective cohort population-based study.Annals of medicine and surgery (2012) · 2024Article
- Analyzing risk factors for second malignancies in early gastric carcinoma from the SEER database.Scientific reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWith the expanding population of cancer survivors, screening for second primary malignancy (SPM) is one issue concerning survivorship care. This study aimed to evaluate the potential risk of developing SPMs and determine the features of SPMs among patients after the diagnosis of gastric cancer (GC).
methodsWe identified 33,705 GC patients from the Surveillance, Epidemiology, and End Results Program (SEER) database. The standardized incidence ratios (SIRs) were calculated to estimate the risk of SPMs. The SIRs were stratified by age, race, stage, and latency period since GC diagnosis.
resultsA total of 2,018 among 33,705 GC patients developed SPMs. Compared with the general population, these GC survivors had higher risks of developing second malignancies of the esophagus, stomach, small intestine, colon, pancreas, and thyroid. Conversely, these GC survivors had lower chances of developing prostate and female breast cancer.
conclusionsIn stratified analyses, we identified the features associated with a higher risk of developing SPMs, including age between 20 and 39 years, latency between 60 and 119 months, localized stage, and American Indian/Alaska Native ethnicity. Hence, GC survivors are at a higher risk of developing SPMs than the general population. Careful attention and continuous surveillance should be used when treating these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.